Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: A pre-specified analysis of the EMPACT-MI trial.
Petrie MC, Udell JA, Anker SD, Harrington J, Jones WS, Mattheus M, Gasior T, van der Meer P, Amir O, Bahit MC, Bauersachs J, Bayes-Genis A, Chopra VK, Januzzi JL, Lopes RD, Ponikowski P, Rossello X, Schou M, Zieroth S, Brueckmann M, Sumin M, Bhatt DL, Hernandez AF, Butler J. Petrie MC, et al. Among authors: bhatt dl. Eur J Heart Fail. 2024 Dec 26. doi: 10.1002/ejhf.3548. Online ahead of print. Eur J Heart Fail. 2024. PMID: 39725521
Influenza Vaccine Immune Response in Patients With High-Risk Cardiovascular Disease: A Secondary Analysis of the INVESTED Randomized Clinical Trial.
Peikert A, Claggett BL, Udell JA, Joseph J, Hegde SM, Kim K, Mao L, Wang T, Havighurst TC, Farkouh ME, Bhatt DL, Tattersall MC, Cooper LS, Solomon SD, Vardeny O. Peikert A, et al. Among authors: bhatt dl. JAMA Cardiol. 2024 Jun 1;9(6):574-581. doi: 10.1001/jamacardio.2024.0468. JAMA Cardiol. 2024. PMID: 38583091 Free PMC article. Clinical Trial.
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Harrington RA, Jukema JW, White HD, Zeiher AM, Manvelian G, Pordy R, Poulouin Y, Stipek W, Garon G, Schwartz GG; ODYSSEY OUTCOMES Investigators. Goodman SG, et al. Among authors: bhatt dl. Eur Heart J Cardiovasc Pharmacother. 2024 Jul 16;10(4):342-352. doi: 10.1093/ehjcvp/pvae025. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38658193 Free PMC article. Review.
Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis.
Usman MS, Bhatt DL, Hameed I, Anker SD, Cheng AYY, Hernandez AF, Jones WS, Khan MS, Petrie MC, Udell JA, Friede T, Butler J. Usman MS, et al. Among authors: bhatt dl. Lancet Diabetes Endocrinol. 2024 Jul;12(7):447-461. doi: 10.1016/S2213-8587(24)00102-5. Epub 2024 May 17. Lancet Diabetes Endocrinol. 2024. PMID: 38768620
Feasibility and Findings of Including Self-Identified Adult Congenital Heart Disease Patients in the INVESTED Trial.
Dehghani P, Srivatsav V, Vardeny O, Grewal J, Opotowsky AR, Muhll IV, Keir M, Ducas R, Singh J, Kim K, Joseph J, Aboulhosn J, Havighurst T, Hegde SM, Bhatt DL, Solomon S, Farkouh M, Goodman SG, Moe TG, Udell JA. Dehghani P, et al. Among authors: bhatt dl. JACC Adv. 2024 Mar 14;3(4):100897. doi: 10.1016/j.jacadv.2024.100897. eCollection 2024 Apr. JACC Adv. 2024. PMID: 38939662 Free PMC article.
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.
Apperloo EM, Neuen BL, Fletcher RA, Jongs N, Anker SD, Bhatt DL, Butler J, Cherney DZI, Herrington WG, Inzucchi SE, Jardine MJ, Liu CC, Mahaffey KW, McGuire DK, McMurray JJV, Neal B, Packer M, Perkovic V, Sabatine MS, Solomon SD, Staplin N, Szarek M, Vaduganathan M, Wanner C, Wheeler DC, Wiviott SD, Zannad F, Heerspink HJL. Apperloo EM, et al. Among authors: bhatt dl. Lancet Diabetes Endocrinol. 2024 Aug;12(8):545-557. doi: 10.1016/S2213-8587(24)00155-4. Epub 2024 Jul 8. Lancet Diabetes Endocrinol. 2024. PMID: 38991584
GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors.
Patel R, Wadid M, Makwana B, Kumar A, Khadke S, Bhatti A, Banker A, Husami Z, Labib S, Venesy D, Fonarow G, Kosiborod M, Al-Kindi S, Bhatt DL, Dani S, Nohria A, Butler J, Ganatra S. Patel R, et al. Among authors: bhatt dl. JACC Heart Fail. 2024 Nov;12(11):1814-1826. doi: 10.1016/j.jchf.2024.07.006. Epub 2024 Aug 28. JACC Heart Fail. 2024. PMID: 39207323
Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis.
Carvalho PEP, Gewehr DM, Nascimento BR, Melo L, Burkhardt G, Rivera A, Braga MAP, Guimarães PO, Mehran R, Windecker S, Valgimigli M, Angiolillo DJ, Bhatt DL, Sandoval Y, Chen SL, Stone GW, Lopes RD. Carvalho PEP, et al. Among authors: bhatt dl. JAMA Cardiol. 2024 Dec 1;9(12):1094-1105. doi: 10.1001/jamacardio.2024.3216. JAMA Cardiol. 2024. PMID: 39382876
Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial.
Roncalli J, Roubille F, Meyer N, Pompilio G, Leroux L, Henon P, Trebuchet G, Criquet A, de Kalbermatten M, Saloux E, Manrique A, Marie PY, Bhatt DL, Solomon SD, Montalescot G, Newby DE, Zannad F; EXCELLENT Trial Investigators. Roncalli J, et al. Among authors: bhatt dl. ESC Heart Fail. 2024 Dec 15. doi: 10.1002/ehf2.15124. Online ahead of print. ESC Heart Fail. 2024. PMID: 39676512 Free article.
2,191 results